



CORPORATE DOSSIER

May 2024



INDEX

About us	5
Our history	5
Vision, mission, and values	6
Growth and Innovation	6
Our clients	7
MEDSIR in numbers	9
What do we do?	10
Together we build a brighter future	10
Our most outstanding studies	13
We prioritize therapeutic strategies based on scientific criteria	17
The founders	18
María Campos	18
Dr. Antonio Llombart	19
Dr. Javier Cortés	19



About us

Our history

MEDSIR is an international company with extensive experience in **designing independent clinical research strategy**. Our activity is focused on discovering, improving, and adapting **innovative treatments for patients with cancer**.

Breast cancer experts, **Dr. Javier Cortés**, **Dr. Antonio Llombart**, along with **María Campos** as executive scientist, founded the company MEDSIR (Medica Scientia Innovation Research) in 2012 with the aim to professionalize independent research under international quality standards. MEDSIR was born with the inclination to innovate and transform the research sector and professionalize the process by which scientific ideas become clinical practice. **For the first time, expert oncology researchers can have comprehensive support for obtaining financing and executing their independent clinical studies.**

In the opinion of María Campos, “the added value of MEDSIR is our ability to innovate study designs for independent clinicians, guiding them to development strategies that will improve the lives of patients.”

We started the company focusing on

designing clinical trials aimed at female patients (cancer of the breast and endometrium) and then we expanded our international network of researchers specialized in all types of tumors; we have even developed clinical trials in other diseases such as COVID-19. (see page 12).

In 2012, oncologists Dr. Javier Cortés and Dr. Antonio Llombart, and executive scientist María Campos, founded MEDSIR to boost independent clinical research in oncology.

Vision, mission, and values

Our **vision** is to become the international medical research company with the greatest impact on the strategic development of new drugs.

Our **mission** is to transform independent clinical research into an efficient and effective scientific strategy.

Ethical and scientific rigor, transparency, methodological agility, internationalization, and diversity are the 5 **values** that define the true essence of MEDSIR and its team of professionals.

Growth and Innovation

In the last 5 years, we have studied a multitude of combinations of cancer treatments, collaborating with **more than 190 hospitals in 14 countries from the European Union**. Thanks to our initiative, patients with breast, prostate, lung, endometrial cancer, and others, including patients with rare tumors such as penile carcinoma or thymic carcinoma, have benefited from our treatments.

The headquarters of MEDSIR is located in Barcelona, Spain, and in addition we have a subsidiary in New Jersey, USA. The team is made up of **more than 100 highly trained and qualified scientific professionals**, with the firm commitment to continue innovating research in oncology with scientific rigor, dynamism, and transparency.

Our clients

MEDSIR promotes the development of proposals among scientists generating ideas in the oncology sector along with the **biotechnology industry that owns innovative drugs**. When joining these

two worlds, we managed to turn ideas from the most brilliant minds into strategic clinical trials with the most promising therapies, all while responding to the needs of each groups involved.

Idea generators or thinkers (researchers)

We work with international medical researchers in clinical and preclinical oncology, and they find in MEDSIR, the right ecosystem to develop their innovative ideas effectively and efficiently.

MEDSIR's added value is our ability to design and execute, as quickly as possible, studies to improve the lives of patients.

María Campos
CEO



Added and differential value of MEDSIR:



Securing of funds



Strategic feasibility study of the investigation project



Network of international experts as support (KOLs)



Preservation of authorship for idea generator

Biotechnology industry with innovative drugs

MEDSIR is committed to helping the pharmaceutical and biotechnology companies, owners of oncological treatments, and they trust our team to develop an optimized strategy for the clinical development of their assets.

Added and differential value of MEDSIR:



International scientific expertise with a strategic vision in the field of oncology



Professional, efficient, and flexible structure, oriented to the scientific value of clinical trials, with an extensive international network of the best oncology research centers. These are some of our collaborators:



Extensive experience in strategic clinical development alliances between companies. These are some of them:



Collaborative development model between the academic world and the biotechnological and pharmaceutical industry

MEDSIR in numbers



12 years of history



59 clinical studies developed



2.455 patients enrolled in our studies



187 hospitals working with us



86 investigators and Key Opinion Leaders in oncology generating innovative ideas for clinical research



432 oncologists already part of our international operational network



160 million euros acquired in the investigation against cancer

35 pharmaceutical and biotech companies have bet on our work



A multidisciplinary team of 108 professionals from 13 different nationalities

What do we do?

Together we build a brighter future

We connect the talent of researchers with the resources of the pharma industry with innovative drugs to create strategic synergies to accelerate the advancement of science.

Our independent and collaborative research model allows us to act with total **flexibility and objectivity** when identifying and developing those studies using innovative and differential science that respond to the real needs of the oncology patients.

We connect the brightest minds in clinical oncology with promising molecules, in order to develop new treatments against cancer.

We look for the perfect match between the world of investigators and that of the pharmaceutical and biotechnology companies.

Alicia García
Scientific Director

Through this unique model, **the researchers preserve the leadership of the project**, staying part of the scientific decision-making and preserving intellectual property.

At MEDSIR we work on the **development and collaborative growth of ideas** as a model that aims to add value to the society. For this reason, we have adopted an approach in which all aspects of the trial - from the scientific to the operational ones- are also discussed and agreed upon with the financing entities so that they are aligned with their strategic objectives.

According to Alicia García, Scientific Director at MEDSIR, “we are looking for the perfect match between the world of research, made up of generators of clinical research ideas, and the pharmaceutical and biotech companies that own the more innovative therapies.”

Cancer is a complex disease that encompasses numerous different pathologies of which there is still much to discover. In this sense, the personalization of therapy based on patient characteristics improves the effectiveness of treatments, and for this reason, **at MEDSIR**

we perform tireless research with the aim of continuing to advance the search for the best therapy options for each patient.

To fulfill our mission, we have a **scientific department with extensive knowledge of the biotechnological sector and large experience in clinical study design**, who, together with the operations department, coordinate comprehensively all processes needed in clinical research ensuring agility, quality, efficiency, effectiveness, and transparency at all moments.



Immunotherapy for patients with COVID-19

At MEDSIR we are an agile organization and can take advantage of our scientific knowledge to combat other diseases

In the first weeks of the COVID-19 pandemic in Europe, a group of MEDSIR collaborating oncologists decided to use their knowledge in immunotherapy to contribute to **research against this new disease.**

For this reason, in April 2020, **we launched the clinical trial COPERNICO:** we wanted to show that the combination of two drugs already used in other pathologies (tocilizumab, an anti-inflammatory drug, and pembrolizumab, an immunotherapy used in oncology) could be effective in the treatment of patients admitted for severe COVID-19. For this, the patients recruited were divided into two groups: a group of patients who continued to receive only standard treatment according to the center's clinical practice, and the other group who received the combination of tocilizumab and pembrolizumab.

The results have been extraordinarily promising. **The group treated with the proposed combination showed faster recovery with a median time to hospital discharge of only 10 days, compared to 47.5 days for patients who received the standard treatment alone.**

[Read in the press](#)

Our most outstanding studies

COPERNICO (COVID-19)

Country: Spain

Relevance: This study investigates whether immunotherapy treatments which have been applied to patients with different types of cancer, are effective in COVID-19 patients who have been admitted to the hospital and are not responding to standard treatment.

Collaborating hospitals: Hospital QuirónSalud Barcelona, Hospital Universitari Vall D'Hebron, Hospital Ramón y Cajal, Hospital Arnau de Vilanova de Valencia (among others)



ORPHEUS (Penile cancer)

Country: Spain, Italy

Relevance: Today, the options of treatment for patients with advanced squamous cell carcinoma of the penis are limited, and the survival rate is less than one year. This study explores an alternative to standard therapeutics and is intended to prolong survival of men with this disease.

Collaborating hospitals: Hospital Santa Creu i Sant Pau, Hospital Universitari Son Espases, Instituto Valenciano de Oncología (IVO), Ospedale San Raffaele, AUSL Reggio Emilia (among others)



PALMIRA (Breast cancer)

Country: Spain, France, Italy, UK, Germany

Relevance: It is expected to show that continuing treatment with palbociclib could be a suitable option in a subtype of breast cancer patients who have obtained an initial clinical benefit with that treatment.

Collaborating hospitals: Hospital Universitari i Politècnic La Fe, Hospital Universitario Miguel Servet, Hopital Europeen Georges Pompidou, Hôpital Tenon AP-HP, Instituto Europeo di Oncologia, Policlinico Universitario Campus Bio-medico Roma, Barts Cancer Institute, Royal Cornwall Hospital NHS Trust, Universitätsklinikum Essen Frauenklinik, Klinikum Rechts der Isar (among others).



PARSIFAL (Breast cancer)

Country: Spain, France, Italy, UK, Germany, Russia, Czech Republic

Relevance: This study is for a subtype of patients with advanced breast cancer who cannot be operated on or treated with radiotherapy with curative intent. The objective is to find out which of the two combinations of drugs being explored are more effective in delaying progression of disease, as well as safer in terms of toxicity.

Collaborating hospitals: Instituto Valenciano de Oncología (IVO), Instituto Oncológico Baselga - Hospital QuironSalud Barcelona, Centre Paul Strauss, Hôpital Tenon AP-HP, AOU policlinico di Modena (among others)



PECATI (Thymic cancer)

Country: Spain, France, Italy

Relevance: One in five patients diagnosed each day with cancer have a rare tumor for which

there is no specific treatment. Thymic carcinoma is one of these very rare tumors in which there are few research opportunities, representing a great unmet therapeutic need. The study could define a new combination of drugs capable of controlling the disease for a longer time.

Collaborating hospitals: Hospital Universitario La Paz, Hospital Universitario Virgen del Rocío, Institut Curie, IGR Gustave Roussy, A.O.U. San Luigi Gonzaga, Royal United Hospitals Bath NHS Foundation Trust, General University Hospital in Prague, Moscow Clinical Scientific Center of the Moscow Health Department (among others)



PHERGAIN-2 (Breast cancer)

Country: Spain, Italy, France, Germany

Relevance: The study aims to demonstrate that in a selected population of early breast cancer patients with good prognosis and high HER2 expression, a therapeutic approach without chemotherapy can be as effective as the current standard of care, while increasing the quality of life of the patients.

Collaborating hospitals: Hospital Universitario Reina Sofía, Complejo Hospitalario Universitario A Coruña (CHUAC), Ospedale Guglielmo da Saliceto, Kliniken Essen Mitte, Hopital Europeen Georges Pompidou (among others)



SLLIP (Lung Cancer)

Country: Spain

Relevance: The objective of this study is to demonstrate that liquid biopsies (blood tests) offer the same information as tissue biopsies (tumor tissue samples), which would allow biological samples to be collected from patients in a less invasive way.

Collaborating hospitals: Institut Català d' Oncologia Badalona (ICO), Hospital del Mar, Hospital Universitari Dexeus, Hospital Universitari Vall D'Hebron (among others)



We prioritize therapeutic strategies based on scientific criteria

Our team of scientific experts design short-, medium-, and long-term therapeutic strategies, **so that new drugs in development are approved more quickly by regulatory agencies and provide a benefit to cancer patients.**

These therapeutic strategies are developed using innovative biostatistical models, international meetings of expert researchers, computational analysis of molecular and clinical data, and a detailed study of the competitive and regulatory environment.

The application of new technologies, both in operational processes and in the analysis of predictive models, are the

Innovation not only includes the design of new therapeutic strategies, but also the way in which studies are implemented to speed up clinical research.

tools that make possible such integration. The flexible and independent model of MEDSIR allow us to speed up phases of the design and execution of tests and, in this way, adapt to the variability of the scientific environment of oncology.

In trial management, clinical criteria and science always prevail in making decisions.



The founders

María Campos

With an international experience of more than 20 years in the field of clinical research and entrepreneurial by nature, María Campos is currently the **Chief Executive Officer (CEO) of MEDSIR**, both for Europe and for the United States.

After several years of research in pharmaceutical companies on breast, lung, and myeloma cancer, her concern for intellectual ideas led her to bet on independent research from a strategic point of view to transfer scientific advances to patients quickly and efficiently. Passionate about technology and digitization, she is a fervent advocate of disruptive change in clinical research that is happening thanks to globalization and the explosion of the world of scientific data.

Supporter of profitable, agile and multidisciplinary thinking, she encourages and preserves the critical spirit and “out of the box” thinking in the world of international scientific research. Outgoing and assertive, María loves getting lost in nature, especially in the mountains, and recharging her batteries by practicing yoga, meditation, and healthy living.

Dr. Antonio Llombart

With an extensive family tradition in the world of scientific research, Antonio Llombart is a medical oncologist with an affable character and great temperance. His strategic ability and his great concern for therapeutic innovation has taken him to currently become the **Head of the Oncology Service at the Arnau de Vilanova University Hospital in Valencia (Spain)**, as well as a European expert and world leader in breast cancer. Passionate about human history and the classical world, he dominates equally well in the entire universe of cancer research after more than 20 years of involvement in the discovery of cancer treatments, such as his membership of the International Scientific Committee in more than 100 international clinical trials. Through his constant intellectual restlessness, he finds the ideal space to enjoy his free time with reading, music or any mental challenge that allows him to reason and solve enigmas.



Dr. Javier Cortés

With a persevering attitude and a very dynamic character, Javier Cortés is currently the **Director of the International Breast Cancer Center (IBCC) and President of the “Fundación Contigo” against Women’s Cancer**. His commitment to the well-being and care of his patients has led him to be, since the beginning, involved in the most innovative and disruptive scientific research becoming one of the most renowned oncologists in the world in the treatment of breast cancer.

Ingenious and restless, he is an active member of the most prestigious medical societies in oncology (ESMO, ASCO, AACR), and a reviewer and advisor to numerous scientific publishers and international consultant for therapeutic innovation in oncology.

In addition to his passion for oncology and his patients, Javier loves life and seeks to disconnect from the intensity of his profession by practicing sports activities in natural environments.



For more information:

